Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06185192 · ClinicalTrials.gov registry record · NA

Efficacy of Viome's Precision Nutrition Program Towards Reducing HbA1c

A NA study of Diabetes, sponsored by Viome.

Recruiting
Registry status
NA
Development phase
100
Enrollment target
1
Study location

NCT06185192: Recruiting NA study of Diabetes, sponsored by Viome.

NCT06185192 is a NA study of Diabetes that is actively recruiting participants, run by Viome. The registered enrollment target is 100 participants, below the 3,028-participant average among 338 other Diabetes trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06185192, a NA study of Diabetes, is actively recruiting participants, sponsored by Viome.

RECRUITING
Registry status
NA
Development phase
100 participants
Enrollment target
1
Study location

Study Summary

This is a randomized, placebo-controlled trial that will test the efficacy of VPNP in reducing HbA1c. Participant recruitment will occur through direct-to-participant enrollment. No additional clinical sites will be used for recruitment.

Primary Outcome

HbA1c changes in individuals in the interventional arm compared to baseline measurement.

Conditions Studied

Interventions

  • DIETARY_SUPPLEMENT Viome's Precision Nutrition Program (VPNP)

Study Locations (1)

Washington

  • Viome Life Sciences - Bothell

Trial Details

FieldValue
Enrollment Target 100 participants
Start Date 2023-12-13
Est. Completion 2026-12
Phase NA
Viome

18 total trials

What NCT06185192 shows while recruiting

NCT06185192 is an interventional study that assigns participants to a tested intervention. The registered 100 participants enrollment target is mid-sized for trials with a published cap, below the 3,028-participant average among 338 other Diabetes trials with a reported enrollment target (97% lower).

The record links to 1 condition, with Diabetes appearing as the primary indexed condition, and to 1 intervention - of which Viome's Precision Nutrition Program (VPNP) is the first listed.

NCT06185192 reports a single indexed study location in Washington.

Frequently Asked Questions

What is clinical trial NCT06185192 about?

NCT06185192 is a clinical study titled "Efficacy of Viome's Precision Nutrition Program Towards Reducing HbA1c". This is a randomized, placebo-controlled trial that will test the efficacy of VPNP in reducing HbA1c. Participant recruitment will occur through direct-to-participant enrollment. No additional clinical sites will be used for recruitment.

What is the current status of trial NCT06185192?

This trial is currently recruiting. It is a NA study. The enrollment target is 100 participants. The study started on 2023-12-13. Estimated completion is 2026-12.

What conditions does trial NCT06185192 study?

This clinical trial studies the following conditions: Diabetes.

What interventions are being tested in trial NCT06185192?

The interventions under investigation include: Viome's Precision Nutrition Program (VPNP) (DIETARY_SUPPLEMENT).

Who is sponsoring clinical trial NCT06185192?

This trial is sponsored by Viome, which has 18 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06185192 being conducted?

This trial has 1 study location across Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Diabetes

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06185192's enrollment target sits among peer trials

100 191st of 338 higher than 144 of 338 other Diabetes trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Diabetes trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01048281 · 100 participants

    Clinical & Pathological Studies of Upper Gastrointestinal Carcinoma

  • NCT01161199 · 100 participants

    The Use of Leukapheresis to Support HIV Pathogenesis Studies

  • NCT01327690 · 100 participants · Early Phase 1

    Mental Health in Veterans and Families After Group Therapies

  • NCT01730781 · 100 participants

    Imaging Cannabinoid Receptors Using Positron Emission Tomography (PET) Scanning

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT06185192, the US trial registry maintained by the National Library of Medicine. NCT06185192 (mid enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.